Schizophrenia Drugs Market By Therapeutic Class (Second Generation, Third Generation, Other), By Treatment (Oral, Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2021-2031
The global schizophrenia drugs market was valued at $7,160.4 million in 2021, and is projected to reach $12,533.2 million by 2031, registering a CAGR of 5.8% from 2022 to 2031.
Schizophrenia is a serious mental disorder in which people interpret reality abnormally. It may result in some combination of hallucinations, delusions, and extremely disordered thinking & behavior that impairs daily functioning, and can be disabling.
It can be triggered by various physical, genetic, psychological and environmental factors. The increase in stressful lifestyle drives the growth of market. In addition, surge in geriatric population drives the growth of market. For instance, according to world health organization (WHO), in 2050, the world’s population of people aged 60 years and older is estimated to reach 2.1 billion. The old age population are prone to late-onset schizophrenia. Thus, rise in stressful lifestyle and mental pressure drives the growth of market.
Furthermore, long term consumption of drugs such as opioids and amphetamines are responsible for some schizophrenia symptoms such as delusions and hallucinations. In addition, illegal consumption of cannabis, cocaine, and LSD may trigger schizophrenia. Furthermore, rise in prevalence of schizophrenia globally, drives the growth of market. For instance, in January 2022, according to world health organization (WHO), schizophrenia affects approximately 24 million people or 1 in 300 people (0.32%) worldwide. Thus, rise in incidences of drug abuse and increase in prevalence of schizophrenia drives the growth of market.
Moreover, the increase in R&D activities for development of Schizophrenia Drugs, rise in United States food and drug administration (USFDA) approvals, and novel product launches in market by key players boost the market growth. For instance, in September 2021, The Janssen Pharmaceutical, a subsidiary of Johnson & Johnson, received U.S. food and drug administration (FDA), long-acting atypical antipsychotic INVEGA HAFYERA (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults. Furthermore, the rise in number of mental disorder clinics and improvement in healthcare infrastructure further contribute in the market growth. However, the lack of appropriate healthcare infrastructure and dearth of adherence to therapy may hinder the growth of market.
The schizophrenia drugs market is segmented on the basis of therapeutic class, treatment, distribution channel, and region. By therapeutic class, the market is classified into second-generation, third-generation, and others. Depending on treatment, the market is divided into oral and injectable. By distribution channel, the market is classified into hospital pharmacy, retail pharmacy, and online pharmacy. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The major companies profiled in the report include Pfizer, AbbVie, Alkermes, AstraZeneca, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck KGAA, Minerva Neurosciences, Novartis AG, Reliance pharmaceuticals, Sumitomo Dainippon, Takeda Pharmaceuticals, Vanda Pharmaceuticals, Viatris (Mylan NV), and Zydus Cadila
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the schizophrenia drugs market analysis from 2021 to 2031 to identify the prevailing schizophrenia drugs market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the schizophrenia drugs market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global schizophrenia drugs market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Treatment
Oral
Injectable
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Therapeutic Class
Second Generation
Third Generation
Other
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Pfizer Inc.
AbbVie
AstraZeneca
Bristol Myers Squibb
Eli Lilly
GlaxoSmithKline
Johnson & Johnson
Merck KGAA
Minerva Neurosciences
Novartis AG
Reliance
Sumitomo Dainippon
Takeda Pharmaceuticals
Vanda Pharmaceuticals
Alkermes
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
- CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO Perspective
- CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter’s five forces analysis
- 3.4.Top player positioning
- 3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
- 3.6.COVID-19 Impact Analysis on the market
- CHAPTER 4: SCHIZOPHRENIA DRUGS MARKET, BY THERAPEUTIC CLASS
- 4.1 Overview
- 4.1.1 Market size and forecast
- 4.2 Second Generation
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
- 4.3 Third Generation
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
- 4.4 Other
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market analysis by country
- CHAPTER 5: SCHIZOPHRENIA DRUGS MARKET, BY TREATMENT
- 5.1 Overview
- 5.1.1 Market size and forecast
- 5.2 Oral
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
- 5.3 Injectable
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
- CHAPTER 6: SCHIZOPHRENIA DRUGS MARKET, BY DISTRIBUTION CHANNEL
- 6.1 Overview
- 6.1.1 Market size and forecast
- 6.2 Hospital Pharmacies
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
- 6.3 Retail Pharmacies
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
- 6.4 Online Pharmacies
- 6.4.1 Key market trends, growth factors and opportunities
- 6.4.2 Market size and forecast, by region
- 6.4.3 Market analysis by country
- CHAPTER 7: SCHIZOPHRENIA DRUGS MARKET, BY REGION
- 7.1 Overview
- 7.1.1 Market size and forecast
- 7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Therapeutic Class
- 7.2.3 North America Market size and forecast, by Treatment
- 7.2.4 North America Market size and forecast, by Distribution Channel
- 7.2.5 North America Market size and forecast, by country
- 7.2.5.1 U.S.
- 7.2.5.1.1 Market size and forecast, by Therapeutic Class
- 7.2.5.1.2 Market size and forecast, by Treatment
- 7.2.5.1.3 Market size and forecast, by Distribution Channel
- 7.2.5.2 Canada
- 7.2.5.2.1 Market size and forecast, by Therapeutic Class
- 7.2.5.2.2 Market size and forecast, by Treatment
- 7.2.5.2.3 Market size and forecast, by Distribution Channel
- 7.2.5.3 Mexico
- 7.2.5.3.1 Market size and forecast, by Therapeutic Class
- 7.2.5.3.2 Market size and forecast, by Treatment
- 7.2.5.3.3 Market size and forecast, by Distribution Channel
- 7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Therapeutic Class
- 7.3.3 Europe Market size and forecast, by Treatment
- 7.3.4 Europe Market size and forecast, by Distribution Channel
- 7.3.5 Europe Market size and forecast, by country
- 7.3.5.1 Germany
- 7.3.5.1.1 Market size and forecast, by Therapeutic Class
- 7.3.5.1.2 Market size and forecast, by Treatment
- 7.3.5.1.3 Market size and forecast, by Distribution Channel
- 7.3.5.2 France
- 7.3.5.2.1 Market size and forecast, by Therapeutic Class
- 7.3.5.2.2 Market size and forecast, by Treatment
- 7.3.5.2.3 Market size and forecast, by Distribution Channel
- 7.3.5.3 U.K.
- 7.3.5.3.1 Market size and forecast, by Therapeutic Class
- 7.3.5.3.2 Market size and forecast, by Treatment
- 7.3.5.3.3 Market size and forecast, by Distribution Channel
- 7.3.5.4 Italy
- 7.3.5.4.1 Market size and forecast, by Therapeutic Class
- 7.3.5.4.2 Market size and forecast, by Treatment
- 7.3.5.4.3 Market size and forecast, by Distribution Channel
- 7.3.5.5 Spain
- 7.3.5.5.1 Market size and forecast, by Therapeutic Class
- 7.3.5.5.2 Market size and forecast, by Treatment
- 7.3.5.5.3 Market size and forecast, by Distribution Channel
- 7.3.5.6 Rest of Europe
- 7.3.5.6.1 Market size and forecast, by Therapeutic Class
- 7.3.5.6.2 Market size and forecast, by Treatment
- 7.3.5.6.3 Market size and forecast, by Distribution Channel
- 7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Therapeutic Class
- 7.4.3 Asia-Pacific Market size and forecast, by Treatment
- 7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
- 7.4.5 Asia-Pacific Market size and forecast, by country
- 7.4.5.1 China
- 7.4.5.1.1 Market size and forecast, by Therapeutic Class
- 7.4.5.1.2 Market size and forecast, by Treatment
- 7.4.5.1.3 Market size and forecast, by Distribution Channel
- 7.4.5.2 Japan
- 7.4.5.2.1 Market size and forecast, by Therapeutic Class
- 7.4.5.2.2 Market size and forecast, by Treatment
- 7.4.5.2.3 Market size and forecast, by Distribution Channel
- 7.4.5.3 India
- 7.4.5.3.1 Market size and forecast, by Therapeutic Class
- 7.4.5.3.2 Market size and forecast, by Treatment
- 7.4.5.3.3 Market size and forecast, by Distribution Channel
- 7.4.5.4 Australia
- 7.4.5.4.1 Market size and forecast, by Therapeutic Class
- 7.4.5.4.2 Market size and forecast, by Treatment
- 7.4.5.4.3 Market size and forecast, by Distribution Channel
- 7.4.5.5 South Korea
- 7.4.5.5.1 Market size and forecast, by Therapeutic Class
- 7.4.5.5.2 Market size and forecast, by Treatment
- 7.4.5.5.3 Market size and forecast, by Distribution Channel
- 7.4.5.6 Rest of Asia-Pacific
- 7.4.5.6.1 Market size and forecast, by Therapeutic Class
- 7.4.5.6.2 Market size and forecast, by Treatment
- 7.4.5.6.3 Market size and forecast, by Distribution Channel
- 7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Therapeutic Class
- 7.5.3 LAMEA Market size and forecast, by Treatment
- 7.5.4 LAMEA Market size and forecast, by Distribution Channel
- 7.5.5 LAMEA Market size and forecast, by country
- 7.5.5.1 Brazil
- 7.5.5.1.1 Market size and forecast, by Therapeutic Class
- 7.5.5.1.2 Market size and forecast, by Treatment
- 7.5.5.1.3 Market size and forecast, by Distribution Channel
- 7.5.5.2 Saudi Arabia
- 7.5.5.2.1 Market size and forecast, by Therapeutic Class
- 7.5.5.2.2 Market size and forecast, by Treatment
- 7.5.5.2.3 Market size and forecast, by Distribution Channel
- 7.5.5.3 South Africa
- 7.5.5.3.1 Market size and forecast, by Therapeutic Class
- 7.5.5.3.2 Market size and forecast, by Treatment
- 7.5.5.3.3 Market size and forecast, by Distribution Channel
- 7.5.5.4 Rest of LAMEA
- 7.5.5.4.1 Market size and forecast, by Therapeutic Class
- 7.5.5.4.2 Market size and forecast, by Treatment
- 7.5.5.4.3 Market size and forecast, by Distribution Channel
- CHAPTER 8: COMPANY LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Key developments
- CHAPTER 9: COMPANY PROFILES
- 9.1 Pfizer Inc.
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
- 9.2 AbbVie
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
- 9.3 AstraZeneca
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
- 9.4 Bristol Myers Squibb
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
- 9.5 Eli Lilly
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
- 9.6 GlaxoSmithKline
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
- 9.7 Johnson & Johnson
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
- 9.8 Merck KGAA
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
- 9.9 Minerva Neurosciences
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
- 9.10 Novartis AG
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments
- 9.11 Reliance
- 9.11.1 Company overview
- 9.11.2 Company snapshot
- 9.11.3 Operating business segments
- 9.11.4 Product portfolio
- 9.11.5 Business performance
- 9.11.6 Key strategic moves and developments
- 9.12 Sumitomo Dainippon
- 9.12.1 Company overview
- 9.12.2 Company snapshot
- 9.12.3 Operating business segments
- 9.12.4 Product portfolio
- 9.12.5 Business performance
- 9.12.6 Key strategic moves and developments
- 9.13 Takeda Pharmaceuticals
- 9.13.1 Company overview
- 9.13.2 Company snapshot
- 9.13.3 Operating business segments
- 9.13.4 Product portfolio
- 9.13.5 Business performance
- 9.13.6 Key strategic moves and developments
- 9.14 Vanda Pharmaceuticals
- 9.14.1 Company overview
- 9.14.2 Company snapshot
- 9.14.3 Operating business segments
- 9.14.4 Product portfolio
- 9.14.5 Business performance
- 9.14.6 Key strategic moves and developments
- 9.15 Alkermes
- 9.15.1 Company overview
- 9.15.2 Company snapshot
- 9.15.3 Operating business segments
- 9.15.4 Product portfolio
- 9.15.5 Business performance
- 9.15.6 Key strategic moves and developments
- LIST OF TABLES
- TABLE 1. GLOBAL SCHIZOPHRENIA DRUGS MARKET, BY THERAPEUTIC CLASS, 2021-2031 ($MILLION)
- TABLE 2. SCHIZOPHRENIA DRUGS MARKET SIZE, FOR SECOND GENERATION, BY REGION, 2021-2031 ($MILLION)
- TABLE 3. SCHIZOPHRENIA DRUGS MARKET FOR SECOND GENERATION BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 4. SCHIZOPHRENIA DRUGS MARKET SIZE, FOR THIRD GENERATION, BY REGION, 2021-2031 ($MILLION)
- TABLE 5. SCHIZOPHRENIA DRUGS MARKET FOR THIRD GENERATION BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 6. SCHIZOPHRENIA DRUGS MARKET SIZE, FOR OTHER, BY REGION, 2021-2031 ($MILLION)
- TABLE 7. SCHIZOPHRENIA DRUGS MARKET FOR OTHER BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 8. GLOBAL SCHIZOPHRENIA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 9. SCHIZOPHRENIA DRUGS MARKET SIZE, FOR ORAL, BY REGION, 2021-2031 ($MILLION)
- TABLE 10. SCHIZOPHRENIA DRUGS MARKET FOR ORAL BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 11. SCHIZOPHRENIA DRUGS MARKET SIZE, FOR INJECTABLE, BY REGION, 2021-2031 ($MILLION)
- TABLE 12. SCHIZOPHRENIA DRUGS MARKET FOR INJECTABLE BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 13. GLOBAL SCHIZOPHRENIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 14. SCHIZOPHRENIA DRUGS MARKET SIZE, FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
- TABLE 15. SCHIZOPHRENIA DRUGS MARKET FOR HOSPITAL PHARMACIES BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 16. SCHIZOPHRENIA DRUGS MARKET SIZE, FOR RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
- TABLE 17. SCHIZOPHRENIA DRUGS MARKET FOR RETAIL PHARMACIES BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 18. SCHIZOPHRENIA DRUGS MARKET SIZE, FOR ONLINE PHARMACIES, BY REGION, 2021-2031 ($MILLION)
- TABLE 19. SCHIZOPHRENIA DRUGS MARKET FOR ONLINE PHARMACIES BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 20. SCHIZOPHRENIA DRUGS MARKET, BY REGION, 2021-2031 ($MILLION)
- TABLE 21. NORTH AMERICA SCHIZOPHRENIA DRUGS MARKET, BY THERAPEUTIC CLASS, 2021-2031 ($MILLION)
- TABLE 22. NORTH AMERICA SCHIZOPHRENIA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 23. NORTH AMERICA SCHIZOPHRENIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 24. NORTH AMERICA SCHIZOPHRENIA DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 25. U.S. SCHIZOPHRENIA DRUGS MARKET, BY THERAPEUTIC CLASS, 2021-2031 ($MILLION)
- TABLE 26. U.S. SCHIZOPHRENIA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 27. U.S. SCHIZOPHRENIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 28. CANADA SCHIZOPHRENIA DRUGS MARKET, BY THERAPEUTIC CLASS, 2021-2031 ($MILLION)
- TABLE 29. CANADA SCHIZOPHRENIA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 30. CANADA SCHIZOPHRENIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 31. MEXICO SCHIZOPHRENIA DRUGS MARKET, BY THERAPEUTIC CLASS, 2021-2031 ($MILLION)
- TABLE 32. MEXICO SCHIZOPHRENIA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 33. MEXICO SCHIZOPHRENIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 34. EUROPE SCHIZOPHRENIA DRUGS MARKET, BY THERAPEUTIC CLASS, 2021-2031 ($MILLION)
- TABLE 35. EUROPE SCHIZOPHRENIA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 36. EUROPE SCHIZOPHRENIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 37. EUROPE SCHIZOPHRENIA DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 38. GERMANY SCHIZOPHRENIA DRUGS MARKET, BY THERAPEUTIC CLASS, 2021-2031 ($MILLION)
- TABLE 39. GERMANY SCHIZOPHRENIA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 40. GERMANY SCHIZOPHRENIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 41. FRANCE SCHIZOPHRENIA DRUGS MARKET, BY THERAPEUTIC CLASS, 2021-2031 ($MILLION)
- TABLE 42. FRANCE SCHIZOPHRENIA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 43. FRANCE SCHIZOPHRENIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 44. U.K. SCHIZOPHRENIA DRUGS MARKET, BY THERAPEUTIC CLASS, 2021-2031 ($MILLION)
- TABLE 45. U.K. SCHIZOPHRENIA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 46. U.K. SCHIZOPHRENIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 47. ITALY SCHIZOPHRENIA DRUGS MARKET, BY THERAPEUTIC CLASS, 2021-2031 ($MILLION)
- TABLE 48. ITALY SCHIZOPHRENIA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 49. ITALY SCHIZOPHRENIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 50. SPAIN SCHIZOPHRENIA DRUGS MARKET, BY THERAPEUTIC CLASS, 2021-2031 ($MILLION)
- TABLE 51. SPAIN SCHIZOPHRENIA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 52. SPAIN SCHIZOPHRENIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 53. REST OF EUROPE SCHIZOPHRENIA DRUGS MARKET, BY THERAPEUTIC CLASS, 2021-2031 ($MILLION)
- TABLE 54. REST OF EUROPE SCHIZOPHRENIA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 55. REST OF EUROPE SCHIZOPHRENIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 56. ASIA-PACIFIC SCHIZOPHRENIA DRUGS MARKET, BY THERAPEUTIC CLASS, 2021-2031 ($MILLION)
- TABLE 57. ASIA-PACIFIC SCHIZOPHRENIA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 58. ASIA-PACIFIC SCHIZOPHRENIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 59. ASIA-PACIFIC SCHIZOPHRENIA DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 60. CHINA SCHIZOPHRENIA DRUGS MARKET, BY THERAPEUTIC CLASS, 2021-2031 ($MILLION)
- TABLE 61. CHINA SCHIZOPHRENIA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 62. CHINA SCHIZOPHRENIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 63. JAPAN SCHIZOPHRENIA DRUGS MARKET, BY THERAPEUTIC CLASS, 2021-2031 ($MILLION)
- TABLE 64. JAPAN SCHIZOPHRENIA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 65. JAPAN SCHIZOPHRENIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 66. INDIA SCHIZOPHRENIA DRUGS MARKET, BY THERAPEUTIC CLASS, 2021-2031 ($MILLION)
- TABLE 67. INDIA SCHIZOPHRENIA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 68. INDIA SCHIZOPHRENIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 69. AUSTRALIA SCHIZOPHRENIA DRUGS MARKET, BY THERAPEUTIC CLASS, 2021-2031 ($MILLION)
- TABLE 70. AUSTRALIA SCHIZOPHRENIA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 71. AUSTRALIA SCHIZOPHRENIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 72. SOUTH KOREA SCHIZOPHRENIA DRUGS MARKET, BY THERAPEUTIC CLASS, 2021-2031 ($MILLION)
- TABLE 73. SOUTH KOREA SCHIZOPHRENIA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 74. SOUTH KOREA SCHIZOPHRENIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 75. REST OF ASIA-PACIFIC SCHIZOPHRENIA DRUGS MARKET, BY THERAPEUTIC CLASS, 2021-2031 ($MILLION)
- TABLE 76. REST OF ASIA-PACIFIC SCHIZOPHRENIA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 77. REST OF ASIA-PACIFIC SCHIZOPHRENIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 78. LAMEA SCHIZOPHRENIA DRUGS MARKET, BY THERAPEUTIC CLASS, 2021-2031 ($MILLION)
- TABLE 79. LAMEA SCHIZOPHRENIA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 80. LAMEA SCHIZOPHRENIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 81. LAMEA SCHIZOPHRENIA DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 82. BRAZIL SCHIZOPHRENIA DRUGS MARKET, BY THERAPEUTIC CLASS, 2021-2031 ($MILLION)
- TABLE 83. BRAZIL SCHIZOPHRENIA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 84. BRAZIL SCHIZOPHRENIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 85. SAUDI ARABIA SCHIZOPHRENIA DRUGS MARKET, BY THERAPEUTIC CLASS, 2021-2031 ($MILLION)
- TABLE 86. SAUDI ARABIA SCHIZOPHRENIA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 87. SAUDI ARABIA SCHIZOPHRENIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 88. SOUTH AFRICA SCHIZOPHRENIA DRUGS MARKET, BY THERAPEUTIC CLASS, 2021-2031 ($MILLION)
- TABLE 89. SOUTH AFRICA SCHIZOPHRENIA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 90. SOUTH AFRICA SCHIZOPHRENIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 91. REST OF LAMEA SCHIZOPHRENIA DRUGS MARKET, BY THERAPEUTIC CLASS, 2021-2031 ($MILLION)
- TABLE 92. REST OF LAMEA SCHIZOPHRENIA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 93. REST OF LAMEA SCHIZOPHRENIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 94.PFIZER INC.: COMPANY SNAPSHOT
- TABLE 95.PFIZER INC.: OPERATING SEGMENTS
- TABLE 96.PFIZER INC.: PRODUCT PORTFOLIO
- TABLE 97.PFIZER INC.: NET SALES,
- TABLE 98.PFIZER INC.: KEY STRATERGIES
- TABLE 99.ABBVIE: COMPANY SNAPSHOT
- TABLE 100.ABBVIE: OPERATING SEGMENTS
- TABLE 101.ABBVIE: PRODUCT PORTFOLIO
- TABLE 102.ABBVIE: NET SALES,
- TABLE 103.ABBVIE: KEY STRATERGIES
- TABLE 104.ASTRAZENECA: COMPANY SNAPSHOT
- TABLE 105.ASTRAZENECA: OPERATING SEGMENTS
- TABLE 106.ASTRAZENECA: PRODUCT PORTFOLIO
- TABLE 107.ASTRAZENECA: NET SALES,
- TABLE 108.ASTRAZENECA: KEY STRATERGIES
- TABLE 109.BRISTOL MYERS SQUIBB: COMPANY SNAPSHOT
- TABLE 110.BRISTOL MYERS SQUIBB: OPERATING SEGMENTS
- TABLE 111.BRISTOL MYERS SQUIBB: PRODUCT PORTFOLIO
- TABLE 112.BRISTOL MYERS SQUIBB: NET SALES,
- TABLE 113.BRISTOL MYERS SQUIBB: KEY STRATERGIES
- TABLE 114.ELI LILLY: COMPANY SNAPSHOT
- TABLE 115.ELI LILLY: OPERATING SEGMENTS
- TABLE 116.ELI LILLY: PRODUCT PORTFOLIO
- TABLE 117.ELI LILLY: NET SALES,
- TABLE 118.ELI LILLY: KEY STRATERGIES
- TABLE 119.GLAXOSMITHKLINE: COMPANY SNAPSHOT
- TABLE 120.GLAXOSMITHKLINE: OPERATING SEGMENTS
- TABLE 121.GLAXOSMITHKLINE: PRODUCT PORTFOLIO
- TABLE 122.GLAXOSMITHKLINE: NET SALES,
- TABLE 123.GLAXOSMITHKLINE: KEY STRATERGIES
- TABLE 124.JOHNSON & JOHNSON: COMPANY SNAPSHOT
- TABLE 125.JOHNSON & JOHNSON: OPERATING SEGMENTS
- TABLE 126.JOHNSON & JOHNSON: PRODUCT PORTFOLIO
- TABLE 127.JOHNSON & JOHNSON: NET SALES,
- TABLE 128.JOHNSON & JOHNSON: KEY STRATERGIES
- TABLE 129.MERCK KGAA: COMPANY SNAPSHOT
- TABLE 130.MERCK KGAA: OPERATING SEGMENTS
- TABLE 131.MERCK KGAA: PRODUCT PORTFOLIO
- TABLE 132.MERCK KGAA: NET SALES,
- TABLE 133.MERCK KGAA: KEY STRATERGIES
- TABLE 134.MINERVA NEUROSCIENCES: COMPANY SNAPSHOT
- TABLE 135.MINERVA NEUROSCIENCES: OPERATING SEGMENTS
- TABLE 136.MINERVA NEUROSCIENCES: PRODUCT PORTFOLIO
- TABLE 137.MINERVA NEUROSCIENCES: NET SALES,
- TABLE 138.MINERVA NEUROSCIENCES: KEY STRATERGIES
- TABLE 139.NOVARTIS AG: COMPANY SNAPSHOT
- TABLE 140.NOVARTIS AG: OPERATING SEGMENTS
- TABLE 141.NOVARTIS AG: PRODUCT PORTFOLIO
- TABLE 142.NOVARTIS AG: NET SALES,
- TABLE 143.NOVARTIS AG: KEY STRATERGIES
- TABLE 144.RELIANCE: COMPANY SNAPSHOT
- TABLE 145.RELIANCE: OPERATING SEGMENTS
- TABLE 146.RELIANCE: PRODUCT PORTFOLIO
- TABLE 147.RELIANCE: NET SALES,
- TABLE 148.RELIANCE: KEY STRATERGIES
- TABLE 149.SUMITOMO DAINIPPON: COMPANY SNAPSHOT
- TABLE 150.SUMITOMO DAINIPPON: OPERATING SEGMENTS
- TABLE 151.SUMITOMO DAINIPPON: PRODUCT PORTFOLIO
- TABLE 152.SUMITOMO DAINIPPON: NET SALES,
- TABLE 153.SUMITOMO DAINIPPON: KEY STRATERGIES
- TABLE 154.TAKEDA PHARMACEUTICALS: COMPANY SNAPSHOT
- TABLE 155.TAKEDA PHARMACEUTICALS: OPERATING SEGMENTS
- TABLE 156.TAKEDA PHARMACEUTICALS: PRODUCT PORTFOLIO
- TABLE 157.TAKEDA PHARMACEUTICALS: NET SALES,
- TABLE 158.TAKEDA PHARMACEUTICALS: KEY STRATERGIES
- TABLE 159.VANDA PHARMACEUTICALS: COMPANY SNAPSHOT
- TABLE 160.VANDA PHARMACEUTICALS: OPERATING SEGMENTS
- TABLE 161.VANDA PHARMACEUTICALS: PRODUCT PORTFOLIO
- TABLE 162.VANDA PHARMACEUTICALS: NET SALES,
- TABLE 163.VANDA PHARMACEUTICALS: KEY STRATERGIES
- TABLE 164.ALKERMES: COMPANY SNAPSHOT
- TABLE 165.ALKERMES: OPERATING SEGMENTS
- TABLE 166.ALKERMES: PRODUCT PORTFOLIO
- TABLE 167.ALKERMES: NET SALES,
- TABLE 168.ALKERMES: KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 1.SCHIZOPHRENIA DRUGS MARKET SEGMENTATION
- FIGURE 2.SCHIZOPHRENIA DRUGS MARKET,2021-2031
- FIGURE 3.SCHIZOPHRENIA DRUGS MARKET,2021-2031
- FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
- FIGURE 5.PORTER FIVE-1
- FIGURE 6.PORTER FIVE-2
- FIGURE 7.PORTER FIVE-3
- FIGURE 8.PORTER FIVE-4
- FIGURE 9.PORTER FIVE-5
- FIGURE 10.TOP PLAYER POSITIONING
- FIGURE 11.SCHIZOPHRENIA DRUGS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
- FIGURE 12.SCHIZOPHRENIA DRUGS MARKET,BY THERAPEUTIC CLASS,2021(%)
- FIGURE 13.COMPARATIVE SHARE ANALYSIS OF SECOND GENERATION SCHIZOPHRENIA DRUGS MARKET,2021-2031(%)
- FIGURE 14.COMPARATIVE SHARE ANALYSIS OF THIRD GENERATION SCHIZOPHRENIA DRUGS MARKET,2021-2031(%)
- FIGURE 15.COMPARATIVE SHARE ANALYSIS OF OTHER SCHIZOPHRENIA DRUGS MARKET,2021-2031(%)
- FIGURE 16.SCHIZOPHRENIA DRUGS MARKET,BY TREATMENT,2021(%)
- FIGURE 17.COMPARATIVE SHARE ANALYSIS OF ORAL SCHIZOPHRENIA DRUGS MARKET,2021-2031(%)
- FIGURE 18.COMPARATIVE SHARE ANALYSIS OF INJECTABLE SCHIZOPHRENIA DRUGS MARKET,2021-2031(%)
- FIGURE 19.SCHIZOPHRENIA DRUGS MARKET,BY DISTRIBUTION CHANNEL,2021(%)
- FIGURE 20.COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACIES SCHIZOPHRENIA DRUGS MARKET,2021-2031(%)
- FIGURE 21.COMPARATIVE SHARE ANALYSIS OF RETAIL PHARMACIES SCHIZOPHRENIA DRUGS MARKET,2021-2031(%)
- FIGURE 22.COMPARATIVE SHARE ANALYSIS OF ONLINE PHARMACIES SCHIZOPHRENIA DRUGS MARKET,2021-2031(%)
- FIGURE 23.SCHIZOPHRENIA DRUGS MARKET BY REGION,2021
- FIGURE 24.U.S. SCHIZOPHRENIA DRUGS MARKET,2021-2031($MILLION)
- FIGURE 25.CANADA SCHIZOPHRENIA DRUGS MARKET,2021-2031($MILLION)
- FIGURE 26.MEXICO SCHIZOPHRENIA DRUGS MARKET,2021-2031($MILLION)
- FIGURE 27.GERMANY SCHIZOPHRENIA DRUGS MARKET,2021-2031($MILLION)
- FIGURE 28.FRANCE SCHIZOPHRENIA DRUGS MARKET,2021-2031($MILLION)
- FIGURE 29.U.K. SCHIZOPHRENIA DRUGS MARKET,2021-2031($MILLION)
- FIGURE 30.ITALY SCHIZOPHRENIA DRUGS MARKET,2021-2031($MILLION)
- FIGURE 31.SPAIN SCHIZOPHRENIA DRUGS MARKET,2021-2031($MILLION)
- FIGURE 32.REST OF EUROPE SCHIZOPHRENIA DRUGS MARKET,2021-2031($MILLION)
- FIGURE 33.CHINA SCHIZOPHRENIA DRUGS MARKET,2021-2031($MILLION)
- FIGURE 34.JAPAN SCHIZOPHRENIA DRUGS MARKET,2021-2031($MILLION)
- FIGURE 35.INDIA SCHIZOPHRENIA DRUGS MARKET,2021-2031($MILLION)
- FIGURE 36.AUSTRALIA SCHIZOPHRENIA DRUGS MARKET,2021-2031($MILLION)
- FIGURE 37.SOUTH KOREA SCHIZOPHRENIA DRUGS MARKET,2021-2031($MILLION)
- FIGURE 38.REST OF ASIA-PACIFIC SCHIZOPHRENIA DRUGS MARKET,2021-2031($MILLION)
- FIGURE 39.BRAZIL SCHIZOPHRENIA DRUGS MARKET,2021-2031($MILLION)
- FIGURE 40.SAUDI ARABIA SCHIZOPHRENIA DRUGS MARKET,2021-2031($MILLION)
- FIGURE 41.SOUTH AFRICA SCHIZOPHRENIA DRUGS MARKET,2021-2031($MILLION)
- FIGURE 42.REST OF LAMEA SCHIZOPHRENIA DRUGS MARKET,2021-2031($MILLION)
- FIGURE 43. TOP WINNING STRATEGIES, BY YEAR
- FIGURE 44. TOP WINNING STRATEGIES, BY DEVELOPMENT
- FIGURE 45. TOP WINNING STRATEGIES, BY COMPANY
- FIGURE 46.PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 47.COMPETITIVE DASHBOARD
- FIGURE 48.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
- FIGURE 49.PFIZER INC..: NET SALES ,($MILLION)
- FIGURE 50.ABBVIE.: NET SALES ,($MILLION)
- FIGURE 51.ASTRAZENECA.: NET SALES ,($MILLION)
- FIGURE 52.BRISTOL MYERS SQUIBB.: NET SALES ,($MILLION)
- FIGURE 53.ELI LILLY.: NET SALES ,($MILLION)
- FIGURE 54.GLAXOSMITHKLINE.: NET SALES ,($MILLION)
- FIGURE 55.JOHNSON & JOHNSON.: NET SALES ,($MILLION)
- FIGURE 56.MERCK KGAA.: NET SALES ,($MILLION)
- FIGURE 57.MINERVA NEUROSCIENCES.: NET SALES ,($MILLION)
- FIGURE 58.NOVARTIS AG.: NET SALES ,($MILLION)
- FIGURE 59.RELIANCE.: NET SALES ,($MILLION)
- FIGURE 60.SUMITOMO DAINIPPON.: NET SALES ,($MILLION)
- FIGURE 61.TAKEDA PHARMACEUTICALS.: NET SALES ,($MILLION)
- FIGURE 62.VANDA PHARMACEUTICALS.: NET SALES ,($MILLION)
- FIGURE 63.ALKERMES.: NET SALES ,($MILLION)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook